Verantos launches Pragmatic Registry product and new registry in severe asthma

The Verantos Pragmatic Registry collects data from a diverse range of sources to generate high-validity real-world evidence and provide valuable insights into specific patient cohorts. The Asthma Pragmatic Registry, produced in collaboration with Amgen, will study people with severe asthma.

Verantos, an international leader in scalable high-validity real-world evidence (RWE), announced that it has launched a Pragmatic Registry product covering cardiovascular, immunology and inflammation, neuroscience, and respiratory therapeutic areas. Built on the Verantos Evidence Platform, the Pragmatic Registry curates real-world data (RWD) collected from various sources, such as health systems, claims, and mortality registries, to provide a comprehensive understanding of the patient experience and journey.

Pragmatic registries are indication-specific registries designed to reflect real-world clinical practice by capturing RWD routinely collected from healthcare providers at academic and community medical centers and health systems. These registries are becoming increasingly important in healthcare research and can complement traditional clinical trials by providing insights into diverse patient populations as well as in real-world settings.

The Pragmatic Registry incorporates industry-standard data elements that can be configured with endpoints and variables, such as symptoms, comorbidities, and biomarkers, which are not available from structured data sources. These elements have been optimized to ensure accuracy, completeness, and traceability, providing a credible source of high-validity RWE for regulators, payers, and clinicians. Compared to the industry average of 50%, the optimized variables within the registry have an accuracy exceeding 80%. Additionally, the registry provides a much larger library of variables, at least five times higher than comparable data sets, based on the linkage of electronic health record (EHR) narrative data, EHR structured data, pharmacy claims, medical claims, and death registries. Furthermore, most of the variables contained within the registry can be traced back to their source, which is substantially higher than the traceability provided by traditional approaches.

Speaking exclusively to The Evidence Base, Anand Shroff, President of Verantos, explained:

“The data sets available via Verantos Pragmatic Registry are among the richest and most complete data sets purpose-built to improve disease-specific knowledge. They are assembled from a number of different data sources and go through a rigorous data cleansing, normalization, standardization, and enrichment process so that life sciences organizations can understand the natural history and progression of disease. These data sets are built to support high-validity evidence generation as well as new use cases such as predictive modelling and training of large language models.”

Verantos also revealed they are collaborating with Amgen on the Asthma Pragmatic Registry. The registry, part of the Food and Drug Administration (FDA) demonstration project called ‘Transforming Real-world evidence with Unstructured and Structured data to advance Tailored therapy (TRUST)’, will include RWD of patients with severe asthma taking medications including biologics, such as Tezspire®.

Brian Bradbury, VP Observational Research at Amgen commented “We are excited to expand our collaboration with Verantos and help contribute to improvements in high quality real-world data collection,” he continued “By gathering and curating this data on patients with severe asthma to support principled real-world evidence generation, Amgen will gain an even deeper understanding into the patient experience, journey, and outcomes.”